Today Stories

Research and development funding has increased: Biopharma funding increased for the second consecutive year in 2024. Total large-pharma R&D spending continued to increase. Clinical trial start volumes have stabilized: Trial starts have fully returned to pre-pandemic levels. Priorities have continued to shift. Clinical program productivity has increased: Improvement in productivity was driven by a success-rate increase in Phase III trials. Cycle times are stabilizing: Enrollment duration – the largest opportunity to improve trial cycle times – stabilized in 2024 after having increased between 2021 and 2023. Inter-trial intervals now typically account for 17 months of total development time across an R&D program; this figure has improved greatly since the 2022 peak of 32 m…

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease control by reducing targeted B cell populations. Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therap…

Russell Abberley, Vice President and General Manager of Amgen UK and Ireland, has been confirmed as ABPI President-elect, having held the role on an interim basis. He will formally take up the Presidency on 13 May for a period of two years. Russell will lead the ABPI in its mission to make the UK the best place in the world to research, develop and launch the medicines and vaccines of the future. His immediate focus will remain on delivering a thriving UK life sciences ecosystem, where patients can access innovative medicines and vaccines and where the right conditions exist to attract global investment. He takes on the role at a pivotal moment, ahead of the publication of the NHS 10-Year Plan and the Life Sciences Sector Plan confident in the role that industry can play in delivering on t…

Hemopatch Sealing Hemostat with room temperature storage now available in Europe New product evolution enables direct accessibility in the operating room  Innovation is a direct result of collaborative efforts with surgeons, helping to ensure that customer needs are met and promoting enhanced patient care  VIENNA - 2025-04-10 Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. "For over a decade, Hemopatch …

Researchers have reported a potential oral treatment for Alzheimer’s disease that slowed its progression over a period of at least 18 months. Developed by Singaporean company TauRx Pharmaceutics Ltd, the scientists based in Aberdeen report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for Alzheimer’s disease (AD) that targets the tau protein pathology – if it is approved by regulators. The findings were revealed at leading international conference AD/PD 2025 in Vienna, which concluded on Saturday. At the event, TauRx Pharmaceuticals CEO and co-founder Professor Claude Wischik outlined work which compared results from HMTM’s recent Phase 3 trial with placebo data from closely matched subjects available from the Critical Path in AD (CPAD) Institute database, whic…

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments OXFORD, UK, and CHICAGO, USA 8th April 2025 – Brainomix, a global leader in AI-powered stroke imaging, has announced the FDA clearance of a novel and patented feature that enables physicians to assess ischemic core volume from universally available non-contrast CT (NCCT) images through the Brainomix 360 Stroke solution. The core volume feature has been studied and validated by leading US stroke centers, with results demonstrating equivalency to CT Perfusion and MRI-derived core volume assessments. This addresses a longstanding unmet need in stroke triage, enabling physicians across stroke networks to access expert-level insights t…

New facility will provide cost-effective manufacturing and clinical testing for pharma and contract research organisations of all sizes. Significant increase in technical positions at BDD helping further strengthen Scotland's life sciences workforce Glasgow, Scotland, 8 April 2025 – Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) in March 2025. Two years in the making, the development of the state-of-the-art facility was facilitated by a funding round of £2 million from existing investors led by the world’s longest running angel investment syndicate, Archangels, with Scottish Enterprise and new investor, British Business…

BioMed X Institute opens its global crowdsourcing platform to help principal investigators in biomedical research who have lost their NIH funding to find alternative project sponsors among the global pharmaceutical industry. Heidelberg, Germany, April 7th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, has announced the launch of its XBridge Program, a fast-track initiative designed to support U.S.-based biomedical researchers impacted by the current NIH funding gaps, hiring freezes, and grant terminations. The program offers a pathway for affected principal investigators in all fields of human disease research. The aim of the program is to connect with potential new research sponsors from the pharmaceutical industry to continue their high-impa…

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit Technologies. The aim of the project is to develop a new generation of targeted alpha-therapeutics by expanding Akiram’s proprietary CD44v6-targeting antibody platform using advanced pre-targeting strategies and radiolabeling chemistry. The PRE-CISE project combines Akiram’s CD44v6-targeting antibody platform with PreTT’s expertise in pre-targeting technology and TetraKit’s radiolabeling chemistry. Using a two-step approach—where the antibody first binds to the tumor, followed by the separate delivery of a radioactive payload—the collaboration aims to unlock access to alpha-emitting radionuclid…

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.  Boehringer Ingelheim strengthens footprint in Swiss biotech innovation hub.  Today NBE Therapeutics (NBE) a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and strengthens its footprint in Switzerland’s biotech ecosystem. NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research strategy. The new facility will serve as a leading research center for advancing…

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C., April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer. Labcorp will also offer a vaginal swab self-collect option for sexually transmitted infection (STI) testing. Both solutions are available by physician order and can be completed privately in a healthcare setting or at any one of Labcorp's 2,200 Patient…

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire(opens new window)/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the JACC, the flagship journal of the American College of Cardiology(opens new window). The Evolut Low Risk Trial was a randomized, multicenter, interna…

New tools to connect with independent in-person and telehealth providers specializing in Alzheimer's disease are designed to increase capacity and reduce delays in diagnosis INDIANAPOLIS, March 27, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease, the majority of whom have not been formally diagnosed.1 Both clinicians and people living with Alzheimer's disease have expressed the need to increase the capacity of our health care systems to diagnose and manage more of the nearly 7 million Americans living with the disease.2 Many patients face prolonged wait times to see a dementia specialist. These wait times are p…

New collaboration aims to deepen understanding of neurodegeneration using the UK’s health data ecosystem The first-of-its-kind study11 will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies1,2,3,4 Collaboration could serve as blueprint for population level health data research and reinforce UK position as a leading life science R&D destination GSK plc (LSE/NYSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to advance understanding of neurodegeneration with a first-of-its-kind dementia study11. The innovative project aims to use the UK’s health data ecosystem to explore…

Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, buildi…

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s research and development and technical operations teams alongside its global and North American commercial organizations into a co-locate…

Cells change shape when they are treated with drugs  New AI technology can accurately show how a cell responds to a drug based on changes to its 3D shape The tech will speed up the development of drugs for a range of diseases by around six years – as years of experiments can be cut from the current preclinical process, and drugs will be less likely to fail in clinical trials The AI tool is being further developed for patient benefit and commercial use by a new company, Sentinal 4D Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to new drugs, by simply observing changes to their shape. The new technology, which has been developed by a team at The Institute of Cancer Research, London, will allow researchers to quickly…

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts New York – March 20, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Studio into ICON’s service offerings helps unlock the full potential of the Medidata Data Experience, merging information from both M…

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318064982/en/ The rapid evolution and miniaturization of semiconductor technology is leading to unprecedented demand for atomic-scale transmission electron microscopy (TEM) metrology data. Manufacturers now face the…

The Fresenius healthcare group is continuously expanding its range of innovative products. A new laboratory and office building with a technical center called KabiLab D20 is being built at Daimlerstrasse 20 on the Fresenius campus in Bad Homburg. It will feature laboratories, a total of 90 desk-sharing workstations, meeting rooms, and storage rooms on an area totaling around 5,000 m2. The move to the new building is planned for mid-2026.  Once completed, around 70 employees from the Fresenius Kabi Business Unit Nutrition currently working in Bad Homburg and Friedberg will relocate to the new building. Among others, they are working on further development of the Fresubin enteral nutrition product portfolio as well as on a special device for producing patient-specific parenteral nutrition. P…